Alicja Puszkiel

7PUBLICATIONS
34CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Epidemiological modellingPharmaceutical delivery technologiesPredictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Feb 06, 2026
Exposure-response relationship of nivolumab and ipilimumab in patients with metastatic renal cell carcinoma from the randomised phase 2 BIONIKK study.

Benoit Blanchet, Alicja Puszkiel, Anne Jouinot

|Dec 10, 2025
Defining Optimally Safe and Effective Blood Levels of Hydroxychloroquine in Lupus: An Important Step Toward Precision Drug Monitoring.

Shivani Garg, Benoît Blanchet, Yann Nguyen

|Mar 27, 2024
Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients.

Alicja Puszkiel, Guillaume Bianconi, Blaise Pasquiers

|Aug 26, 2023
Translation of Monoclonal Antibodies Pharmacokinetics from Animal to Human Using Physiologically Based Modeling in Open Systems Pharmacology (OSP) Suite: A Retrospective Analysis of Bevacizumab.

Blaise Pasquiers, Salih Benamara, Mathieu Felices

|Oct 14, 2022
Monitoring of Dabrafenib and Trametinib in Serum and Self-Sampled Capillary Blood in Patients with BRAFV600-Mutant Melanoma.

Nora Isberner, Anja Gesierich, David Balakirouchenane

|Sep 23, 2022
Exposure-Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer.

Thomas Rodier, Alicja Puszkiel, Evelina Cardoso

Pageof 2

Frequent Collaborators

2 joint publications

Monia Guidi

2 joint publications

Xavier Declèves

1 joint publications

David Balakirouchenane

1 joint publications

Sarah Guégan